Peyrl A - Search Results

1

High frequency of mosaicism among patients with neurofibromatosis type 1 (NF1) with microdeletions caused by somatic recombination of the JJAZ1 gene.

Kehrer-Sawatzki H, Kluwe L, Sandig C, Kohn M, Wimmer K, Krammer U, Peyrl A, Jenne DE, Hansmann I, Mautner VF. Kehrer-Sawatzki H, et al. Among authors: peyrl a. Am J Hum Genet. 2004 Sep;75(3):410-23. doi: 10.1086/423624. Epub 2004 Jul 15. Am J Hum Genet. 2004. PMID: 15257518 Free PMC article.

2

RNA-based mutation analysis identifies an unusual MSH6 splicing defect and circumvents PMS2 pseudogene interference.

Etzler J, Peyrl A, Zatkova A, Schildhaus HU, Ficek A, Merkelbach-Bruse S, Kratz CP, Attarbaschi A, Hainfellner JA, Yao S, Messiaen L, Slavc I, Wimmer K. Etzler J, et al. Among authors: peyrl a. Hum Mutat. 2008 Feb;29(2):299-305. doi: 10.1002/humu.20657. Hum Mutat. 2008. PMID: 18030674

3

Brain tumors - other treatment modalities.

Peyrl A, Frischer J, Hainfellner JA, Preusser M, Dieckmann K, Marosi C. Peyrl A, et al. Handb Clin Neurol. 2017;145:547-560. doi: 10.1016/B978-0-12-802395-2.00034-1. Handb Clin Neurol. 2017. PMID: 28987193 Review.

4

Protein profiles of medulloblastoma cell lines DAOY and D283: identification of tumor-related proteins and principles.

Peyrl A, Krapfenbauer K, Slavc I, Yang JW, Strobel T, Lubec G. Peyrl A, et al. Proteomics. 2003 Sep;3(9):1781-800. doi: 10.1002/pmic.200300460. Proteomics. 2003. PMID: 12973738

5

Proteomic characterization of the human cortical neuronal cell line HCN-2.

Peyrl A, Krapfenbauer K, Slavc I, Strobel T, Lubec G. Peyrl A, et al. J Chem Neuroanat. 2003 Nov;26(3):171-8. doi: 10.1016/s0891-0618(03)00079-6. J Chem Neuroanat. 2003. PMID: 14615026

6

Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years.

Peyrl A, Sauermann R, Traunmueller F, Azizi AA, Gruber-Olipitz M, Gupper A, Slavc I. Peyrl A, et al. Clin Pharmacokinet. 2009;48(4):265-71. doi: 10.2165/00003088-200948040-00004. Clin Pharmacokinet. 2009. PMID: 19492871

7

Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies.

Gojo J, Sauermann R, Knaack U, Slavc I, Peyrl A. Gojo J, et al. Among authors: peyrl a. Drugs R D. 2017 Sep;17(3):469-474. doi: 10.1007/s40268-017-0190-z. Drugs R D. 2017. PMID: 28577293 Free PMC article.

8

Protein Profiling of the Supratentorial Primitive Neuroectodermal Tumor (PNET) Cell Line PFSK-1.

Peyrl A, Krapfenbauer K, Afjehi-Sadat L, Strobel T, Slavc I, Lubec G. Peyrl A, et al. Cancer Genomics Proteomics. 2004 Mar-Apr;1(2):125-136. Epub 2004 Mar 1. Cancer Genomics Proteomics. 2004. PMID: 31394677 Free article.

9

Feasibility and tolerability of bevacizumab in children with primary CNS tumors.

Reismüller B, Azizi AA, Peyrl A, Heinrich M, Gruber-Olipitz M, Luckner D, Rothschild KV, Slavc I. Reismüller B, et al. Among authors: peyrl a. Pediatr Blood Cancer. 2010 May;54(5):681-6. doi: 10.1002/pbc.22409. Pediatr Blood Cancer. 2010. PMID: 20066713

10

Tumor stabilization under treatment with imatinib in progressive hypothalamic-chiasmatic glioma.

Peyrl A, Azizi A, Czech T, Gruber-Olipitz M, Jones N, Haberler C, Prayer D, Autzinger E, Slavc I. Peyrl A, et al. Pediatr Blood Cancer. 2009 Apr;52(4):476-80. doi: 10.1002/pbc.21881. Pediatr Blood Cancer. 2009. PMID: 19061223 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75 results

Search Page

Filters